SCHEMBL11925210

SCHEMBL11925210

CC(C)NS(=O)(=O)c1cc(C(=O)NN2CC3C4CCC(C4)C3C2)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ GLA P06280 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CNR2 P34972 3/20 0.46
▸ GSTO1 P78417 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ CA4 P22748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13815370 1.00 KDM4E (0.47) KDM4EHTTLMNAGLAMAPT
SCHEMBL14394547 0.89 LMNA (0.47) KDM4EHTTLMNAGLAMAPT
SCHEMBL11929104 0.89 LMNA (0.47) KDM4EHTTLMNAGLAMAPT
SCHEMBL20368993 0.86 KDM4E (0.44) KDM4EHTTLMNAGLAMAPT
Tripamide SCHEMBL1651231 0.84 KDM4E (0.59) KDM4EHTTLMNAGLAMAPT
Tripamide SCHEMBL49666 0.84 KDM4E (0.59) KDM4EHTTLMNAGLAMAPT
Tripamide SCHEMBL4442559 0.74 KDM4E (0.46) KDM4EHTTLMNAGLAMAPT
SCHEMBL9195738 0.73 KDM4E (0.71) KDM4EHTTMAPTHSD17B10GSTO1
SCHEMBL10281734 0.71 ALDH1A1 (0.75) KDM4EHTTLMNAGLAMAPT
SCHEMBL5504213 0.67 KDM4E (0.59) KDM4EHTTHSD17B10GSTO1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194732-A1 MULTI-API LOADING PRODRUGS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-07-12 — — US disclosed
US-20180194732-A1 MULTI-API LOADING PRODRUGS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-07-12 — — US disclosed
US-20160024011-A1 Multi-API Loading Prodrugs ALKERMES PHARMA IRELAND LTD (IE) 2016-01-28 — — US disclosed
US-20120202823-A1 Multi-API Loading Prodrugs ALKERMES, INC. 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024011-A1 Multi-API Loading Prodrugs AADAC, PAICS, ABCG2 KDM4E 423/4885HTT 3691/4885LMNA 2855/4885
US-20120202823-A1 Multi-API Loading Prodrugs AADAC, PAICS, ABCG2 KDM4E 423/4885HTT 3691/4885LMNA 2855/4885
US-20180194732-A1 MULTI-API LOADING PRODRUGS AADAC, PAICS, ABCG2 KDM4E 423/4885HTT 3691/4885LMNA 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback